Serum Institute of India acquires 20% stake in IntegriMedical
Summary
The largest vaccine manufacturer in the world, Serum Institute of India (SII), purchased a 20% share in IntegriMedical, a US-based company, in order to further the development of needle-free injection system technology.The deals financial specifics were kept under wraps.In a statement released on Friday, Pune-based SII said that the collaboration with IntegriMedical is in line with both companys goals of "Health for All" and "Transforming Healthcare Globally" through the provision of patient comfort, assurance of improved patient compliance, a decrease in needle-stick injuries, and an improvement in the effectiveness of liquid medication through needle-free dispersion.IntegriMedical has created a needle-free injection system (N-FIS) that is patented in the US and uses mechanical power to create high-velocity jet streams for the administration of medications and biologics.SII claims that N-FIS will soon be offered on the private Indian market. The Needle-Free Injection Systems (N-FIS) from IntegriMedical mark a substantial breakthrough in medication delivery, and we hope to provide vaccinations without the need for needles. According to Adar Poonawalla, CEO of SII, "We think this could potentially revolutionise the way we administer vaccines, making the process more comfortable for patients and healthcare professionals. "The goal of SII and IntegriMedicals partnership is to combine their strengths in vaccine production, cutting-edge medication delivery technologies, and strong research backgrounds.The announcement read, "Together, the companies aim to expand access to care and improve efficiencies in the global healthcare industry. "The investment by SII, according to IntegriMedicals MD Sarvesh Mutha, is evidence of the companys N-FIS technologys promise to transform medicine delivery.